The FDA determined that the 3-dose Pfizer COVID-19 vaccine worked in children aged 6 months through 4 years; the bipartisan Senate gun deal will focuses on mental health; the pandemic has other viruses acting mysteriously, with children diagnosed with respiratory viruses in May and June.
The 3-dose COVID-19 vaccine from Pfizer and BioNTech was found to have worked in young children aged 6 months to 4 years, according to The Wall Street Journal. The FDA also found that the data proved that there were no new safety concerns with using the vaccine in young children compared with the rest of the population. This announcement comes mere days from when an FDA staff review found that the Moderna vaccine was also safe for young children of the same age group. These findings could indicate that the vaccine will be made available to this age group soon, with the Biden administration saying that vaccinations for young children could be made available by June 21.
A bipartisan gun deal from Senators Debbie Stabenow (D-Mich.) and Roy Blunt (R-Mo.) would include funding for community mental health clinics nationwide that would provide mental health crisis response, substance abuse treatment, and other services around the clock, according to The Hill. The measure would expand the mental health clinic program, which currently only has 10 states fully participating. The framework released by the 20 senators who are working on the bill called for “major investments to increase access to mental health and suicide prevention programs” although no hard figure was provided.
Viruses which are typically limited to the winter months, including respiratory syncytial virus and the flu, are becoming more common in the summer months, according to The Washington Post. Due to this increase in virus cases outside of their usual season, doctors are thinking of keeping more vaccinesn on hand in the spring and summer. Epidemiologists are also looking into what stay-at-home orders, masking, and social distancing may have done to affect virus cases thereafter. Researchers and doctors suggest that the removal of masks and gatherings held indoors when population immunity was low may have been the cause of the increase in out-of-season virus cases.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More